Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10912286 | Lung Cancer | 2005 | 8 Pages |
Abstract
Although both 3- and 4-week gemcitabine regimens were safely and effectively administered in chemonaive elderly patients with advanced NSCLC, the 3-week schedule appears to be the more convenient for this population. Moreover, even if this is only a phase II study this 3-week schedule appears to be at least as efficient as the 4-week regimen.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Elisabeth Quoix, Jean-Luc Breton, Alain Ducoloné, Bertrand Mennecier, Alain Depierre, Etienne Lemarié, Denis Moro-Sibilot, Caroline Germa, Anne-Catherine Neidhardt,